--本文经《美国外科病理学杂志》授权发布，其他媒体转载或引用须经《美国外科病理学杂志》同意，否则追究法律责任。
 

　　混合性神经内分泌-非神经内分泌肿瘤(mixed neuroendocrine-nonneuroendocrine neoplasm, MiNEN)由腺瘤与分化好的神经内分泌肿瘤（neuroendocrine tumor, NET)组成，最近被定义为"MANET"。然而，这类肿瘤的临床病理特点及发病机制并不明确。我们通过检测12例MANET病例中p53和β-联蛋白的表达及瘤体中2种不同肿瘤成分的微卫星不稳定和KRAS、BRAF以及PIK3CA基因突变来分析这类肿瘤的临床病理特点。所有病例中，腺瘤成分都是病变的主体，而NET成分则位于息肉深部的中央。根据NET成分将肿瘤分级，9例为NET G1, 2例为NET G2, 1例为NET G3。所有病例中，腺体与NET成分混杂生长，二者之间可见移行区域。所有病例NET成分的p53均为阴性，8例中有3例出现不同程度的β-联蛋白细胞核阳性。所有病例平均随访9年后均无病存活。肿瘤中两种成分均未检测到KRAS、BRAF和PIK3CA基因突变以及微卫星不稳定。我们回顾之前文献报 道过的59例MANET,也未发现因为肿瘤导致的死亡。伴有低分化神经内分泌癌成分的高级别恶性MiNEN,类似于混合性腺瘤-神经内分泌癌，目前推测两种肿瘤中的成分可能是同一来源。因此，尽管目前研究表明MANET是一种惰性肿瘤，但仍需和侵袭性高级别MiNEN相鉴别。

Am J Surg Pathol 2018;42:1503-1512

美国外科病理学杂志中文版2019年第二期摘要NO.7

(许素素 翻译  滕梁红 审校）

　　©2018 Wolters Kluwer Health

　　The material is published by Wolters Kluwer Health with the permission of American Journal of Surgical Pathology.No part of this publication may be reproduced in any form,stored in a retrieval system or transmitted in any form,by any means,without prior written permission from Wolters Kluwer Health.Opinions expressed by the authors and advertisers are not necessarily those of the American Journal of Surgical Pathology, its affiliates,or of the Publisher.The American Journal of Surgical Pathology,its affiliates,and the Publisher disclaim any liability to any party for the accuracy,completeness,efficacy,or availability of the material contained in this publication (including drug dosages) or for any damages arising out of the use or non-use of any of the material contained in this publication.

　　Although advertising material is expected to conform to ethical (medical) standards,inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.